By selecting the Yes option, leaving Amgen.eu option you understand that you are leaving the corporate page of Amgen Europe and that you will be redirected to another Internet site belonging to third parties, for whose content or opinions Amgen Europe is not responsible and makes no representations regarding such content or its accuracy. By selecting this option and accessing linked third party sites, you understand that you do so at your own risk.

The website to which you will be redirected may be designed exclusively for residents of a particular country or countries, as advertised on that website. As a consequence, the website to which you will be directed may contain information on pharmaceutical products or indications that are not approved in Europe. If You reside in a country other than the one to which such website is directed, please contact your local Amgen affiliate for the correct information on products in your country of residence.

yes, leave amgen.eu CANCEL

Osteoporosis and Fragility Fractures: A policy toolkit

Osteoporosis and Fragility Fractures: A policy toolkit

By Victoria Tzouma, Sr. Manager, International Government Affairs & Policy

Osteoporosis has a significant burden on the European population and health systems, with 1 in 2 women and 1 in 5 men over 50 experiencing a fragility fracture in their lifetime.1 This will often lead to a loss of mobility, independence and reduced quality of life.2 More concerning, hip fractures double the risk of death3 and increase the risk of subsequent fractures.4 Yet, the majority of people with fragility fractures are not being diagnosed and treated with effective therapies that could reduce this risk. EU healthcare systems pay almost €57 billion annually5 for fragility fractures, which is significantly higher than for many other leading chronic diseases. As the United Nations have declared 2021-2030 as the decade of healthy ageing, now is the time to prioritise bone health and implement policies to address its clinical and economic burden across Europe. The “Osteoporosis and Fragility Fractures: a Policy Toolkit”, created by the Health Policy Partnership in 2020 and funded by Amgen, calls for immediate action at European, national and local levels and provides building blocks for an effective policy response.

References

  1. “Osteoporosis and fragility fractures A policy toolkit.” The Health Policy Partnership & Amgen. February 2022.
  2. Hernlund E, Svedbom A, Ivergard M, et al. 2013. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8: 136
  3. Ross PD. 1997. Clinical consequences of vertebral fractures. Am J Med 103(2a): 30S-42S; discussion 42S-43S 2
  4. Katsoulis M, Benetou V, Karapetyan T, et al. 2017. Excess mortality after hip fracture in elderly persons from Europe and the USA: the CHANCES project. J Intern Med 281(3): 300-10
  5. Christiansen B.A, et al. Osteoporos Int. 2018;29:2201–2209
  6. “SCOPE 2021 A New Scorecard for Osteoporosis In Europe.” International Osteoporosis Foundation. https://www.osteoporosis.foundation/sites/iofbonehealth/files/2022-01/Slide%20set%20-%20EU%20general.pdf